{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T02:13:01Z","timestamp":1769047981435,"version":"3.49.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,12]],"date-time":"2017-05-12T00:00:00Z","timestamp":1494547200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lrjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.leukres.2017.05.006","type":"journal-article","created":{"date-parts":[[2017,5,9]],"date-time":"2017-05-09T21:17:50Z","timestamp":1494364670000},"page":"12-19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Red blood cell alloimmunization in 184 patients with myeloid neoplasms treated with azacitidine \u2013 A retrospective single center experience"],"prefix":"10.1016","volume":"59","author":[{"given":"M.","family":"Leisch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Lindlbauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Jungbauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Egle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Rohde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Greil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Grabmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Pleyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2017.05.006_bib0005","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1056\/NEJMra0902908","article-title":"Myelodysplastic syndromes","volume":"361","author":"Tefferi","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2017.05.006_bib0010","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.05.006_bib0015","first-page":"5","article-title":"Cancer statistics, 2015","volume":"65","author":"Siegel","year":"2015","journal-title":"CA: Cancer J. Clin."},{"key":"10.1016\/j.leukres.2017.05.006_bib0020","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet. Oncol."},{"key":"10.1016\/j.leukres.2017.05.006_bib0025","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1200\/JCO.2009.23.8329","article-title":"Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia","volume":"28","author":"Fenaux","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2017.05.006_bib0030","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s40265-016-0585-0","article-title":"Azacitidine a review in myelodysplastic syndromes and acute myeloid leukaemia","volume":"76","author":"Scott","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.leukres.2017.05.006_bib0035","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.05.006_bib0040","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/ajh.24396","article-title":"Chronic myelomonocytic leukemia: 2016 update on diagnosis, risk stratification, and management","volume":"91","author":"Patnaik","year":"2016","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2017.05.006_bib0045","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2015-08-604520","article-title":"An update of current treatments for adult acute myeloid leukemia","volume":"127","author":"Dombret","year":"2016","journal-title":"Blood"},{"issue":"32","key":"10.1016\/j.leukres.2017.05.006_bib0050","article-title":"Azacitidine in patients with WHO-defined AML \u2013 results of 155 patients from the austrian azacitidine registry of the AGMT-Study group","volume":"6","author":"Pleyer","year":"2013","journal-title":"J. Hematol. Oncol."},{"issue":"39","key":"10.1016\/j.leukres.2017.05.006_bib0055","article-title":"Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications","volume":"9","author":"Pleyer","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.leukres.2017.05.006_bib0060","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1007\/s00277-014-2126-9","article-title":"Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group","volume":"93","author":"Pleyer","year":"2014","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.leukres.2017.05.006_bib0065","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.leukres.2014.01.006","article-title":"Azacitidine in CMML: matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival","volume":"38","author":"Pleyer","year":"2014","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2017.05.006_bib0070","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1537-2995.2006.00708.x","article-title":"Red blood cell alloantibodies after transfusion: factors influencing incidence and specificity","volume":"46","author":"Schonewille","year":"2006","journal-title":"Transfusion (Paris)"},{"key":"10.1016\/j.leukres.2017.05.006_bib0075","doi-asserted-by":"crossref","first-page":"503","DOI":"10.7205\/MILMED-D-02-5808","article-title":"Estimation of combat-related blood group alloimmunization and delayed serologic transfusion reactions in U.S. military veterans","volume":"174","author":"Tormey","year":"2009","journal-title":"Mil. Med."},{"key":"10.1016\/j.leukres.2017.05.006_bib0080","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/sj.bmt.1704114","article-title":"Red blood cell support and alloimmunization rate against erythrocyte antigens in patients undergoing hematopoietic stem cell transplantation","volume":"32","author":"Perseghin","year":"2003","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.leukres.2017.05.006_bib0085","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1537-2995.2011.03502.x","article-title":"Red blood cell alloimmunization in sickle cell anemia: more questions than answers?","volume":"52","author":"Campbell-Lee","year":"2012","journal-title":"Transfusion (Paris)"},{"key":"10.1016\/j.leukres.2017.05.006_bib0090","first-page":"624","article-title":"Increased incidence of red blood cell alloantibodies in myelodysplastic syndrome","volume":"17","author":"Rozovski","year":"2015","journal-title":"Isr. Med. Assoc. J.: IMAJ"},{"key":"10.1016\/j.leukres.2017.05.006_bib0095","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.tmrv.2014.04.008","article-title":"Red blood cell alloimmunization mitigation strategies","volume":"28","author":"Hendrickson","year":"2014","journal-title":"Transfus. Med. Rev."},{"key":"10.1016\/j.leukres.2017.05.006_bib0100","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/j.1537-2995.2012.03819.x","article-title":"Red blood cell alloimmunization in transfused patients with myelodysplastic syndrome or chronic myelomonocytic leukemia","volume":"53","author":"Sanz","year":"2013","journal-title":"Transfusion (Paris)"},{"key":"10.1016\/j.leukres.2017.05.006_bib0105","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s002770100308","article-title":"Red cell antibodies in frequently transfused patients with myelodysplastic syndrome","volume":"80","author":"Stiegler","year":"2001","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.leukres.2017.05.006_bib0110","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1423-0410.2011.01517.x","article-title":"Red-blood-cell alloimmunization and number of red-blood-cell transfusions","volume":"102","author":"Zalpuri","year":"2012","journal-title":"Vox Sang."},{"key":"10.1016\/j.leukres.2017.05.006_bib0115","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1046\/j.1537-2995.1999.39070763.x","article-title":"Alloimmunization after blood transfusion in patients with hematologic and oncologic diseases","volume":"39","author":"Schonewille","year":"1999","journal-title":"Transfusion (Paris)"},{"key":"10.1016\/j.leukres.2017.05.006_bib0120","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/trf.13379","article-title":"Impact of red blood cell alloimmunization on sickle cell disease mortality: a case series","volume":"56","author":"Nickel","year":"2016","journal-title":"Transfusion (Paris)"},{"key":"10.1016\/j.leukres.2017.05.006_bib0125","first-page":"3671","article-title":"Report of an international working group to standardize response criteria for myelodysplastic syndromes","volume":"96","author":"Cheson","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.05.006_bib0130","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2017.05.006_bib0135","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.05.006_bib0140","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1182\/blood.V92.7.2322","article-title":"The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The medical research council adult and children's leukaemia working parties","volume":"92","author":"Grimwade","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.05.006_bib0145","doi-asserted-by":"crossref","first-page":"861","DOI":"10.5858\/arpa.2012-0154-CR","article-title":"Limiting the extent of a delayed hemolytic transfusion reaction with automated red blood cell exchange","volume":"137","author":"Tormey","year":"2013","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.leukres.2017.05.006_bib0150","first-page":"1","article-title":"Impact of azacitidine on red blood cell alloimmunisation in myelodysplastic syndrome","author":"Ortiz","year":"2016","journal-title":"Blood Trans. = Trasfusione del sangue"},{"key":"10.1016\/j.leukres.2017.05.006_bib0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000046525","article-title":"Immunohematological findings in myelodysplastic syndrome","volume":"105","author":"Novaretti","year":"2001","journal-title":"Acta Haematol."},{"key":"10.1016\/j.leukres.2017.05.006_bib0160","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/j.1537-2995.2011.03329.x","article-title":"Providing ABO-identical platelets and cryoprecipitate to (almost) all patients: approach, logistics, and associated decreases in transfusion reaction and red blood cell alloimmunization incidence","volume":"52","author":"Henrichs","year":"2012","journal-title":"Transfusion (Paris)"},{"key":"10.1016\/j.leukres.2017.05.006_bib0165","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1046\/j.1537-2995.1984.24384225031.x","article-title":"Erythrocyte antigens on human platelets. Absence of Rh, Duffy, Kell, Kidd, and Lutheran antigens","volume":"24","author":"Dunstan","year":"1984","journal-title":"Transfusion (Paris)"},{"key":"10.1016\/j.leukres.2017.05.006_bib0170","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/bjh.13781","article-title":"Chronic inflammatory autoimmune disorders are a risk factor for red blood cell alloimmunization","volume":"174","author":"Ryder","year":"2016","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2017.05.006_bib0175","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/bjh.13123","article-title":"Red blood cell alloimmunization is influenced by recipient inflammatory state at time of transfusion in patients with sickle cell disease","volume":"168","author":"Fasano","year":"2015","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2017.05.006_bib0180","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18020415","article-title":"Azacitidine for front-line therapy of patients with AML: reproducible efficacy established by direct comparison of international phase 3 trial data with registry data from the austrian azacitidine registry of the AGMT study group","volume":"18","author":"Pleyer","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.leukres.2017.05.006_bib0185","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1423-0410.2011.01542.x","article-title":"High-throughput multiplex PCR genotyping for 35 red blood cell antigens in blood donors","volume":"102","author":"Jungbauer","year":"2012","journal-title":"Vox Sang."},{"key":"10.1016\/j.leukres.2017.05.006_bib0190","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/trf.13347","article-title":"Incidence of alloantibody formation after ABO-D or extended matched red blood cell transfusions: a randomized trial (MATCH study)","volume":"56","author":"Schonewille","year":"2016","journal-title":"Transfusion (Paris)"},{"key":"10.1016\/j.leukres.2017.05.006_bib0195","first-page":"53","article-title":"Molecular matching for Rh and K reduces red blood cell alloimmunisation in patients with myelodysplastic syndrome","volume":"13","author":"Guelsin","year":"2015","journal-title":"Blood Trans. = Trasfusione del sangue"},{"key":"10.1016\/j.leukres.2017.05.006_bib0200","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the eastern cooperative oncology group","volume":"5","author":"Oken","year":"1982","journal-title":"Am. J. Clin. Oncol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212617304204?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212617304204?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T05:31:15Z","timestamp":1602048675000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212617304204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":40,"alternative-id":["S0145212617304204"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2017.05.006","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Red blood cell alloimmunization in 184 patients with myeloid neoplasms treated with azacitidine \u2013 A retrospective single center experience","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2017.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}